312. Gene Correction of LGMD2A Patient-Specific iPS Cells for Targeted Autologous Cell Therapy

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33121-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Stem Cell Therapy for Ischemic Stroke Using iPS Cells

Clinical Neurology
Neurology
2013English

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

Scientific Reports
Multidisciplinary
2019English

Cell Cycle-Specific Changes in hTERT Promoter Activity in Normal and Cancerous Cells in Adenoviral Gene Therapy: A Promising Implication of Telomerase-Dependent Targeted Cancer Gene Therapy

International Journal of Oncology
Cancer ResearchOncology
2006English

Mesenchymal Stem Cells: A Promising Tool for Targeted Gene Therapy of Endometriosis

Regenerative Medicine
EmbryologyBiomedical Engineering
2017English

Single-Agent Plerixafor Mobilization to Collect Autologous Stem Cells for Use in Gene Therapy for Severe Sickle Cell Disease

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Platelet-Targeted Gene Therapy for Hemophilia

Molecular Therapy - Methods and Clinical Development
Molecular MedicineGeneticsMolecular Biology
2018English

Promoters With Cancer Cell-Specific Activity for Melanoma Gene Therapy

Acta Naturae
BiochemistryBiotechnologyMolecular MedicineMolecular Biology
2011English

Correction To: Differentiation of RPE Cells From Integration-Free iPS Cells and Their Cell Biological Characterization

Stem Cell Research and Therapy
GeneticsCell BiologyMolecular BiologyBiochemistryMedicineMolecular Medicine
2019English

Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and Therapy

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy